GBI Research
has released its pharma report "Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline
Drugs to Drive Growth".
The systemic
psoriasis market is forecast to grow substantially over the forecast period
from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major
markets. This growth will be driven by a rising treatment population and the
continued uptake of biologics.
Biologics
will continue to drive market growth despite leading brands Enbrel
(etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent
protection in most of the major markets over the forecast period. Although the
market will suffer revenue losses as a result of sales erosion from biosimilar
competitors, this will be offset by the emergence of novel therapies.
View Full Report with TOC @ http://www.radiantinsights.com/research/systemic-psoriasis-therapeutics-in-major-developed-markets-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth
Most
notably, these include monoclonal antibodies secukinumab, ixekizumab and
brodalumab, which are currently being developed by Alcon (Novartis subsidiary),
Eli Lilly and Amgen, respectively.
Scope
- An
introduction to psoriasis, which includes symptoms, epidemiology, etiology,
pathophysiology, diagnosis and treatment
- Analysis
of the major systemic therapies in the current psoriasis marketed landscape
- Analysis
of the pipeline for psoriasis, which includes a breakdown of pipeline molecules
by phase of development, molecule type, molecular target and novelty. Psoriasis
clinical trials are analyzed by size, duration and failure rates, and a
comparative analysis of the most promising systemic pipeline molecules is also
provided.
- Forecast
projections for the systemic psoriasis market to 2020. Analysis is provided for
the global market and each of the eight major markets. The forecast
incorporates projected, low and high variance scenarios based on treatment
usage patterns and annual therapy costs in each of the major markets.
- Analysis
of strategic consolidations, including co-development and licensing deals,
within the psoriasis indication
Reasons to buy
- Understand
the current systemic psoriasis marketed products landscape and recognize the
dominant therapeutic agents and pharmaceutical players involved
- Identify
trends and developments within the psoriasis pipeline and consider how the
future competitive environment will be impacted
- Consider market
opportunities and potential risks by examining the psoriasis clinical trial
landscape in relation to industry averages
- Observe
projections for treatment usage patterns, annual therapy costs and market
growth in the eight major markets and understand reasons for variance in
projected patterns of growth in the eight major markets
About Us
Radiant Insights is a platform for companies
looking to meet their market research and business intelligence requirements.
We assist and facilitate organizations and individuals procure market research
reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro
markets. In addition to over extensive database of reports, our experienced
research coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For
more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog
URL: http://www.esorics2010.org/
No comments:
Post a Comment